Bay Area's Arcus Biosciences Scores $107M, Initiates Two Clinical Trials Post author:Sam Post published:November 12, 2017 Post category:BioPharma Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing. Source: BioSpace You Might Also Like DBV Technologies Crashed as Allergy Drug Flunked Phase III Test October 22, 2017 Qiagen Plans to Create Up to 800 Jobs at New UK Campus Post Brexit November 26, 2017 Horizon Pharma Launches CGD Connections To Deliver Support And Resources Created By And For The Chronic Granulomatous Disease (CGD) Community July 24, 2017
Horizon Pharma Launches CGD Connections To Deliver Support And Resources Created By And For The Chronic Granulomatous Disease (CGD) Community July 24, 2017